期刊
TRANSFUSION MEDICINE AND HEMOTHERAPY
卷 45, 期 2, 页码 86-91出版社
KARGER
DOI: 10.1159/000488060
关键词
Extended half-life; Factor concentrates; Hemophilia A and B; Prophylaxis
资金
- Swedish Orphan Biovitrum AG
- Octapharma AG
- Novo Nordisk Pharma AG
- CSL Behring AG
In the last couple of years, several extended half-life factor VIII and factor IX preparations were intensively studied and gained approval. In order to extend half-lives, techniques like fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification are implemented. With these techniques, it is possible to extend half-lives of factor IX products 4- to 6-fold, while half-life extension of factor VIII products is limited to 1.5- to 2-fold due to their interaction with von Willebrand factor. Nevertheless, both extended half-life factor VIII and IX products have improved and facilitated prophylactic factor replacement therapy in hemophilia A and B, respectively. Extended half-life factor concentrates pose challenges to coagulation laboratories because accurate therapy monitoring is not possible with all factor activity assays currently used. (c) 2018 S. Karger GmbH, Freiburg
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据